The role of COMT inhibition in the treatment of Parkinson's disease

Neurology

Volumn 62, Issue 1 SUPPL. 1, 2004, Pages

  Poewe, Werner ^a   Koller, ^b   LeWitt, ^b   Jenner, ^b   Brooks, ^b   Hauser, ^b   Reinikainen, ^b   Hubble, ^b  

^a UNIVERSITY OF INNSBRUCK   (Austria)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

CATECHOL METHYLTRANSFERASE INHIBITOR; DOPAMINE RECEPTOR STIMULATING AGENT; ENTACAPONE; LEVODOPA; PLACEBO; SELEGILINE; TOLCAPONE;

CLINICAL PRACTICE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG EFFECT; DRUG FATALITY; DRUG MIXTURE; DYSKINESIA; HUMAN; LIVER TOXICITY; MONOTHERAPY; MOTOR DYSFUNCTION; PARKINSON DISEASE; PRIORITY JOURNAL; PROSPECTIVE STUDY; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL; REVIEW; SCORING SYSTEM;

EID: 0347092050     PISSN: 00283878     EISSN: None     Source Type: Journal    
DOI: 10.1212/wnl.62.1_suppl_1.s31     Document Type: Review

References (23)

1. Rinne UK, Bracco F, Chouza C, et al. Cabergoline in the treatment of early Parkinson's disease: results of the first year of treatment in a double-blind comparison of cabergoline and levodopa. Neurology 1997;48:363-368.
2. Rinne UK, Bracco F, Chouza C, et al., and the PKDS009 Study Group. Early treatment of Parkinson's disease with cabergoline delays the onset of motor complications. Drugs 1998;55(suppl 1):23-30.
3. Rascol O, Brooks DJ, Korczyn AD, et al. A five-year study of the incidence of dyskinesia in patients with early Parkinson's disease who were treated with ropinirole or levodopa. N Engl J Med 2000;342:1484-1491.
4. Parkinson Study Group. Pramipexole vs. levodopa as initial treatment for Parkinson's disease. JAMA 2000;284:1931-1938.
5. Oertel WH. Pergolide versus L-dopa (PELMOPET). Mov Dis 2000;15(suppl 3)4:2000. Abstract.
6. Parkinson Study Group. Entacapone improves motor fluctuations in levodopa-treated Parkinson's disease patients. Ann Neurol 1997;42:747-755.
7. Schrag A, Quinn N. Dyskinesias and motor fluctuations in Parkinson's disease. A community-based study. Brain 2000;123:2297-2305.
8. Poewe W, Wenning G. Levodopa in Parkinson's disease: mechanisms of action and pathophysiology of late failure. In: Jankovic J, Tolosa E, eds. Parkinson's disease and movement disorders. Vol. 8. 4th ed. Lippincott Williams & Wilkins, 2002;104-115.
9. Olanow W, Schapira AH, Rascol O. Continuous dopamine-receptor stimulation in early Parkinson's disease. Trends Neurosci 2000;23:117-126.
10. Männistö PT, Kaakkola S. Catechol O-methyltransferase (COMT). Biochemistry, molecular biology, pharmacology and clinical efficacy of the new selective COMT inhibitors. Pharmacol Rev 1999;51:593-628.
11. Nissinen E, Linden IB, Schultz E, Pohto P. Biochemical and pharmacological properties of a peripherally acting catechol-O-methyltransferase inhibitor entacapone. Naunyn Schmiedebergs Arch Pharmacol 1992;346:262-266.
12. Männistö PT, Ulmanen I, Lundström K, et al. Characteristics of catechol O-methyttransferase (COMT) and properties of selective COMT inhibitors. Prog Drug Res 1992;39:291-350.
13. Nutt JG, Woodward WR, Beckner RM, et al. Effect of peripheral catechol-O-methyltransferase inhibition on the pharmacokinetics and pharmacodynamics of levodopa in parkinsonian patients. Neurology 1994;44:913-919.
14. Ruottinen HM, Rinne UK. Entacapone prolongs levodopa response in a one-month double-blind study in parkinsonian patients with levodopa related fluctuations. J Neurol Neurosurg Psych 1996;60:36-40.
15. Kaakkola S. Clinical pharmacology, therapeutic use and potential of COMT inhibitors in Parkinson's disease. Drugs 2000;59:1233-1250.
16. Rinne UK, Larsen JP, Siden A, Worm-Petersen J, and the NOMECOMT Study Group. Entacapone enhances the response to levodopa in parkinsonian patients with motor fluctuations. Neurology 1998;51:1309-1314.
17. Poewe W, Deuschl G, Gordin A, Kultalahti ER, Leinonen M, and the CELOMEN Study Group. Efficacy and safety of entacapone in Parkinson's disease patients with suboptimal levodopa response: a six-month randomised placebo-controlled double-blind study in Germany and Austria (CELOMEN study). Acta Neurol Scand 2002;105:245-255.
18. Brooks DJ, Sagar H, and the UK-IRISH Entacapone Study Group. Entacapone is beneficial in both fluctuating and non-fluctuating patients with Parkinson's disease. A randomised, placebo-controlled, double-blind six-month study. J Neurol Neurosurg Psychiatry 2003;74:1071-1079.
19. Larsen JP, Worm-Petersen J, Siden A, Gordin A, Reinikainen K, Leinonen M, and the NOMESAFE Study Group. The tolerability and efficacy of entacapone over three years in patients with Parkinson's disease. Eur J Neurol 2003;10:137-146.
20. Hubble JP, Guarneri M, Olanow CW. Effects of entacapone in Parkinson's disease patients without end of dose wearing off. Neurology 2003;60:289-290.
21. Durif F, Devaux I, Pere JJ, Delumeau JC, Bourdeix I. Efficacy and tolerability of entacapone as adjunctive therapy to levodopa in patients with Parkinson's disease and end-of-dose deterioration in daily medical practice: an open, multicenter study. Eur Neurol 2001;45:111-118.
22. Geishanik O, Emre M, Bernhard G, Sauer D. Efficacy and safety of levodopa with entacapone in Parkinson's disease patients suboptimally controlled with levodopa alone, in daily clinical practice: an international, multicentre, open-label study. Prog Neuropsychopharmacol Biol Psychiatry 2003;74:1064-1072.
23. Goetz CG, Koller WC, Poewe W, Rascol O, Sampaio C. Management of Parkinson's disease: an evidence-based review. Mov Disord 2002;17(suppl 4):S45-S51.